Detalles de la búsqueda
1.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38728430
2.
Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.
Eur J Nucl Med Mol Imaging
; 51(8): 2293-2307, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38456971
3.
Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models.
J Magn Reson Imaging
; 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38733369
4.
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
BMC Cancer
; 23(1): 1132, 2023 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37990162
5.
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
Haematologica
; 107(8): 1891-1901, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045690
6.
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Blood
; 128(9): 1226-33, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27458004
7.
Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation.
Br J Haematol
; 196(1): 244-248, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431093
8.
Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.
Haematologica
; 102(8): 1432-1438, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28495913
9.
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Br J Haematol
; 173(5): 731-41, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26990892
10.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer
; 16: 290, 2016 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114074
11.
Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.
Eur Radiol
; 26(11): 3939-3948, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26767378
12.
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Am J Hematol
; 91(11): E473-E477, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27508939
13.
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
Haematologica
; 100(6): 818-25, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25795721
14.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica
; 100(7): 964-9, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25840597
15.
The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states.
J Cancer Res Clin Oncol
; 150(2): 55, 2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291214
16.
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.
Amyloid
; 31(2): 86-94, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38206120
17.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia
; 38(3): 640-647, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38062124
18.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38302221
19.
Genomic Classification and Individualized Prognosis in Multiple Myeloma.
J Clin Oncol
; 42(11): 1229-1240, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194610
20.
Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.
Haematologica
; 103(4): e162-e164, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29419430